Market revenue in 2022 | USD 56.1 million |
Market revenue in 2030 | USD 131.9 million |
Growth rate | 11.3% (CAGR from 2022 to 2030) |
Largest segment | 13-24 weeks |
Fastest growing segment | 0-12 weeks |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | 0-12 weeks, 13-24 weeks, 25-36 weeks |
Key market players worldwide | CooperSurgical, Natera Inc, Eurofins Scientific SE, Illumina Inc, Centogene NV Ordinary Shares, MedGenome, Myriad Genetics Inc, Roche Holding AG, Qiagen NV, Labcorp Holdings Inc, Quest Diagnostics Inc, Biora Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non invasive prenatal testing market will help companies and investors design strategic landscapes.
13-24 weeks was the largest segment with a revenue share of 52.41% in 2022. Horizon Databook has segmented the South Korea non invasive prenatal testing market based on 0-12 weeks, 13-24 weeks, 25-36 weeks covering the revenue growth of each sub-segment from 2018 to 2030.
In South Korea, the proportion of elderly pregnant women has dramatic rise in elderly pregnancy has raised worries about the high risk of fetal aneuploidies. In South Korea, the expected number of infants with Down syndrome is 4.5 per 10,000 births.
According to South Korean government statistics, more than 97.5% of pregnant women are given some form of serum screening test for detecting fetal aneuploidies during pregnancy. Increasing R&D investments by key pharmaceutical companies in South Korea are expected to create a lucrative environment for market growth.
For instance, in December 2019, Roche Diagnostics Korea announced plans to encourage the use of a non-invasive prenatal test (NIPT) in the Korean market. In 2016, the business launched its NIPT, Harmony, in the local market. To send retrieved samples to U.S. testing institutions and receive results, the firm used the "test and send out" (TSO) technique.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea non invasive prenatal testing market , including forecasts for subscribers. This country databook contains high-level insights into South Korea non invasive prenatal testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account